Weekly Digest – October 2025 Weekly Digest – October 2025 30 September 2025: Henlius receives the NMPA IND approval for Its PD-L1 targeting ADC HLX43 in combination with novel anti-EGFR mAb HLX07 The China NMPA approved Henlius’ IND application for […]
Weekly Digest – October 2025 Weekly Digest – October 2025 29 September 2025: Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase 3 trial in patients with high-risk early breast cancer […]
Weekly Digest – October 2025 Weekly Digest – October 2025 30 September 2025: Starpharma announces a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset Starpharma signed a research and option agreement with Radiopharm Theranostics after […]
Weekly Digest – October 2025 Weekly Digest – October 2025 30 September 2025: Debiopharm licenses SunRock Biopharma’s anti-HER3/HER2 antibody to explore the full potential of bispecific ADC Debio 2512 Debiopharm licensed SunRock Biopharma’s bispecific HER3/HER2 antibody SRB21 to develop a […]
Weekly Digest – September 2025 Weekly Digest – September 2025 24 September 2025: Enhertu plus Pertuzumab granted priority review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer The FDA has granted priority review to Enhertu […]
Weekly Digest – September 2025 Weekly Digest – September 2025 22 September 2025: Huadong Medicine’s CDH17-targeted ADC HDM2017 IND application received FDA approval in the US The U.S. FDA approved Huadong Medicine’s IND application for HDM2017, a CDH17-targeted ADC, allowing […]
Weekly Digest – September 2025 Weekly Digest – September 2025 25 September 2025: Qurient and Synaffix partner to develop next-generation dual-payload ADCs Qurient entered into a licensing agreement with Synaffix (a Lonza subsidiary) to develop next-generation dual-payload ADCs, integrating Qurient’s […]
Weekly Digest – September 2025 Weekly Digest – September 2025 23 September 2025: TegMine Therapeutics enters collaboration with Boehringer Ingelheim to advance Novel 2-Factor antibody system for cancer TegMine Therapeutics entered a strategic R&D collaboration with Boehringer Ingelheim to advance […]
Weekly Digest – September 2025 Weekly Digest – September 2025 22 September 2025: Mabwell Bioscience, Insilico Medicine, and ChemExpress forging ahead with ADC innovation through strategic collaboration Mabwell Bioscience, Insilico Medicine, and ChemExpress formed a strategic collaboration to jointly develop […]
Weekly Digest – September 2025 Weekly Digest – September 2025 24 September 2025: Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811) Hengrui Pharma granted Glenmark exclusive rights (excluding major markets like China, US, […]
